botaretigene sparoparvovec
AXP000260.1 · Viral vector gene therapy
- Platform
- AAV5 vector
- Targets
- RPGR
- Originator
- MeiraGTx
- Sponsor
- Johnson & Johnson
Names
| Name | Type | Source |
|---|---|---|
| botaretigene sparoparvovec | preferred name | curator |
| bota-vec | synonym | curator |
| AAV-RPGR | former code | curator |
| MGT009 | former code | curator |
Virus
- Role
- In vivo gene transfer
- Family
- Parvoviridae
- Virus
- adeno-associated virus 5
- Strain
- AAV5
- Replication
- non replicating
- Transgenes
- RPGR
- Route
- subretinal
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (3)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06646289 | A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP) | Active not recruiting | Phase 2 | 2024-10-10 | 2030-10-24 | 24 | X-Linked Retinitis Pigmentosa |
| NCT04794101 | Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene | Active not recruiting | Phase 3 | 2020-12-04 | 2029-09-20 | 97 | X-Linked Retinitis Pigmentosa |
| NCT04671433 | Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene | Completed | Phase 3 | 2020-12-04 | 2024-09-30 | 105 | X-Linked Retinitis Pigmentosa |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42847595 | Microperimetry Sensitivity Changes at the Functional Transition Zone and at the EZ Margins in X-Linked Retinitis Pigmentosa Treated With Gene Therapy. | Translational vision science & technology | 2026 | name in abstract: AAV-RPGR |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42576225 | Efficacy and safety of AAV RPGR gene therapy in X-linked retinitis pigmentosa: a systematic review and meta-analysis. | Journal of translational medicine | 2026 | name in title: AAV-RPGR |
| PMID 42652548 | Functional Outcomes and Ocular Safety of Subretinal AAV-RPGR Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa: A Systematic Review and Meta-Analysis. | Journal of clinical medicine | 2026 | name in title: AAV-RPGR |
| PMID 38339118 | AAV-RPGR Gene Therapy Rescues Opsin Mislocalisation in a Human Retinal Organoid Model of RPGR-Associated X-Linked Retinitis Pigmentosa. | International journal of molecular sciences | 2024 | name in title: AAV-RPGR |
| PMID 31612744 | RPGR gene therapy presents challenges in cloning the coding sequence. | Expert opinion on biological therapy | 2020 | name in abstract: AAV-RPGR |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| ZIAEY000443 | Ocular Gene Therapy | NATIONAL EYE INSTITUTE | WU, ZHIJIAN | 2017–2017 | name in abstract: AAV-RPGR |
Notes
AAV5 vector delivering RPGR to rod and cone photoreceptors for X-linked retinitis pigmentosa, given subretinally. Phase 1/2 NCT03252847 and phase 3 LUMEOS NCT04671433. Formerly MGT009 / AAV-RPGR. The J&J product page first cited for the AAV5/RPGR facts has gone; they now rest on the Retinal Physician and Ophthalmology Management reviews, which say the same.
How to cite
botaretigene sparoparvovec (AXP000260.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000260.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.